Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
作者信息
Naismith Robert T, Bourdette Dennis
出版信息
Neurology. 2011 May 31;76(22):1854-5. doi: 10.1212/WNL.0b013e31821d7553. Epub 2011 May 4.
PMID:21543735
Abstract
摘要
相似文献
1
Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
Neurology. 2011 May 31;76(22):1854-5. doi: 10.1212/WNL.0b013e31821d7553. Epub 2011 May 4.
2
Natalizumab and progressive multifocal leukoencephalopathy.
N Engl J Med. 2005 Jul 28;353(4):432-3. doi: 10.1056/NEJMc055235. Epub 2005 Jun 9.
3
Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
Neurology. 2007 May 1;68(18):1524-8. doi: 10.1212/01.wnl.0000260699.09720.ad.
4
Natalizumab for relapsing multiple sclerosis.
N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9.
5
Natalizumab for relapsing multiple sclerosis.
N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9. doi: 10.1056/NEJMc060894.
6
Natalizumab for relapsing multiple sclerosis.
N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9.
7
Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
N Engl J Med. 2005 Jul 28;353(4):414-6. doi: 10.1056/NEJMe058122. Epub 2005 Jun 9.
8
Rituximab in relapsing-remitting multiple sclerosis.
N Engl J Med. 2008 Jun 12;358(24):2645; author reply 2646-7.
9
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Curr Opin Neurol. 2006 Aug;19(4):341-9. doi: 10.1097/01.wco.0000236612.66839.a2.
10
[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Duodecim. 2013;129(7):765-70.
Zotero 插件